SMC accepts darolutamide in mHSPC in combination with docetaxel – What is the impact on clinical practice in Scotland?
Expert insights video with Professor Rob Jones
Professor Rob Jones, Consultant Medical Oncologist at the Beatson West of Scotland Cancer Centre, Glasgow , provides his perspective on how the SMC acceptance of NUBEQA for the treatment of mHSPC in combination with docetaxel will impact clinical practice in Scotland.
Within this bitesize video, Professor Jones explores:
His treatment goals for patients with mHSPC and how these patients have been treated historically
The impact of SMC accepting darolutamide in combination with docetaxel and ADT for treatment of mHSPC
Who should be offered NUBEQA in combination with docetaxel and ADT, and the rationale for treatment intensification for chemo-eligible patients
This video is organised and funded by Bayer plc.
Speakers
Professor Robert Jones
Professor Jones is Director, Cancer Clinical Trials Unit for Scotland, professor of clinical cancer research at the University of Glasgow and a consultant medical oncologist at the Beatson West of Scotland Cancer Centre.
After undergraduate training at the Universities of Oxford and Edinburgh, Rob moved to Glasgow to train in internal medicine and then Medical Oncology. His clinical practice is the medical management of cancers of the prostate, bladder and kidney. His research commitments include the management of a large portfolio of phase I, II and III trials as well as collaborative translational research.
Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email: pvuk@bayer.com.
If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.
